AARD
Aardvark Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.86 EPS
Last earnings -4.9% on 2026-05-07
$4.79
▼ -5.34%$4.79▼ -64.23%
over 1Y
L $3.48EODHDH $17.41
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-5.3%
1W-5.3%
1M+20.1%
3M+34.9%
YTD-63.7%
1Y-64.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 18 analysts
Buy
Conservative balance sheet (liabilities/equity 0.10x).
Revenue (FY2025) $0.00 · FY2025
Aardvark Therapeutics, Inc. shows $0.00 in FY2025 revenue, and -54.0% ROE.
Financials · annual, by fiscal year
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | $0.00 |
| Gross profit | — | — |
| Operating income | -$22.8M | -$62.7M |
| Net income | -$20.6M | -$57.6M |
| Diluted EPS | -$5.15 | -$2.93 |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$57.4M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-55.1%
FCF yield-51.9%
Quality & risk
ROIC (est.)-46.5%
Free cash flow-$54.3M
Total debt—
Net cash$47.1M
Altman Z-Score3.83 safe
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗EFFECTFiling2026-04-03open ↗424B5Filing2026-04-03open ↗CORRESPFiling2026-03-30open ↗UPLOADFiling2026-03-25open ↗8-KPeriod ending 2026-03-232026-03-24open ↗S-8Filing2026-03-24open ↗S-3Filing2026-03-23open ↗10-KPeriod ending 2025-12-312026-03-23open ↗
Frequently asked
- Is Aardvark Therapeutics, Inc. (AARD) a buy?
- AARD currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.10x).
- What is Aardvark Therapeutics, Inc.'s quality score?
- AARD scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001774857, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:16:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.